Cargando…

Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma

OBJECTIVES: The application of susceptibility weighted imaging (SWI) in brain tumor imaging is mainly used to assess tumor-related “susceptibility based signals” (SBS). The origin of SBS in glioblastoma is still unknown, potentially representing calcifications or blood depositions. Reliable differen...

Descripción completa

Detalles Bibliográficos
Autores principales: Deistung, Andreas, Schweser, Ferdinand, Wiestler, Benedikt, Abello, Mario, Roethke, Matthias, Sahm, Felix, Wick, Wolfgang, Nagel, Armin Michael, Heiland, Sabine, Schlemmer, Heinz-Peter, Bendszus, Martin, Reichenbach, Jürgen Rainer, Radbruch, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605431/
https://www.ncbi.nlm.nih.gov/pubmed/23555565
http://dx.doi.org/10.1371/journal.pone.0057924
_version_ 1782263890051072000
author Deistung, Andreas
Schweser, Ferdinand
Wiestler, Benedikt
Abello, Mario
Roethke, Matthias
Sahm, Felix
Wick, Wolfgang
Nagel, Armin Michael
Heiland, Sabine
Schlemmer, Heinz-Peter
Bendszus, Martin
Reichenbach, Jürgen Rainer
Radbruch, Alexander
author_facet Deistung, Andreas
Schweser, Ferdinand
Wiestler, Benedikt
Abello, Mario
Roethke, Matthias
Sahm, Felix
Wick, Wolfgang
Nagel, Armin Michael
Heiland, Sabine
Schlemmer, Heinz-Peter
Bendszus, Martin
Reichenbach, Jürgen Rainer
Radbruch, Alexander
author_sort Deistung, Andreas
collection PubMed
description OBJECTIVES: The application of susceptibility weighted imaging (SWI) in brain tumor imaging is mainly used to assess tumor-related “susceptibility based signals” (SBS). The origin of SBS in glioblastoma is still unknown, potentially representing calcifications or blood depositions. Reliable differentiation between both entities may be important to evaluate treatment response and to identify glioblastoma with oligodendroglial components that are supposed to present calcifications. Since calcifications and blood deposits are difficult to differentiate using conventional MRI, we investigated whether a new post-processing approach, quantitative susceptibility mapping (QSM), is able to distinguish between both entities reliably. MATERIALS AND METHODS: SWI, FLAIR, and T1-w images were acquired from 46 patients with glioblastoma (14 newly diagnosed, 24 treated with radiochemotherapy, 8 treated with radiochemotherapy and additional anti-angiogenic medication). Susceptibility maps were calculated from SWI data. All glioblastoma were evaluated for the appearance of hypointense or hyperintense correlates of SBS on the susceptibility maps. RESULTS: 43 of 46 glioblastoma presented only hyperintense intratumoral SBS on susceptibility maps, indicating blood deposits. Additional hypointense correlates of tumor-related SBS on susceptibility maps, indicating calcification, were identified in 2 patients being treated with radiochemotherapy and in one patient being treated with additional anti-angiogenic medication. Histopathologic reports revealed an oligodendroglial component in one patient that presented calcifications on susceptibility maps. CONCLUSIONS: QSM provides a quantitative, local MRI contrast, which reliably differentiates between blood deposits and calcifications. Thus, quantitative susceptibility mapping appears promising to identify rare variants of glioblastoma with oligodendroglial components non-invasively and may allow monitoring the role of calcification in the context of different therapy regimes.
format Online
Article
Text
id pubmed-3605431
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36054312013-04-03 Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma Deistung, Andreas Schweser, Ferdinand Wiestler, Benedikt Abello, Mario Roethke, Matthias Sahm, Felix Wick, Wolfgang Nagel, Armin Michael Heiland, Sabine Schlemmer, Heinz-Peter Bendszus, Martin Reichenbach, Jürgen Rainer Radbruch, Alexander PLoS One Research Article OBJECTIVES: The application of susceptibility weighted imaging (SWI) in brain tumor imaging is mainly used to assess tumor-related “susceptibility based signals” (SBS). The origin of SBS in glioblastoma is still unknown, potentially representing calcifications or blood depositions. Reliable differentiation between both entities may be important to evaluate treatment response and to identify glioblastoma with oligodendroglial components that are supposed to present calcifications. Since calcifications and blood deposits are difficult to differentiate using conventional MRI, we investigated whether a new post-processing approach, quantitative susceptibility mapping (QSM), is able to distinguish between both entities reliably. MATERIALS AND METHODS: SWI, FLAIR, and T1-w images were acquired from 46 patients with glioblastoma (14 newly diagnosed, 24 treated with radiochemotherapy, 8 treated with radiochemotherapy and additional anti-angiogenic medication). Susceptibility maps were calculated from SWI data. All glioblastoma were evaluated for the appearance of hypointense or hyperintense correlates of SBS on the susceptibility maps. RESULTS: 43 of 46 glioblastoma presented only hyperintense intratumoral SBS on susceptibility maps, indicating blood deposits. Additional hypointense correlates of tumor-related SBS on susceptibility maps, indicating calcification, were identified in 2 patients being treated with radiochemotherapy and in one patient being treated with additional anti-angiogenic medication. Histopathologic reports revealed an oligodendroglial component in one patient that presented calcifications on susceptibility maps. CONCLUSIONS: QSM provides a quantitative, local MRI contrast, which reliably differentiates between blood deposits and calcifications. Thus, quantitative susceptibility mapping appears promising to identify rare variants of glioblastoma with oligodendroglial components non-invasively and may allow monitoring the role of calcification in the context of different therapy regimes. Public Library of Science 2013-03-21 /pmc/articles/PMC3605431/ /pubmed/23555565 http://dx.doi.org/10.1371/journal.pone.0057924 Text en © 2013 Deistung et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Deistung, Andreas
Schweser, Ferdinand
Wiestler, Benedikt
Abello, Mario
Roethke, Matthias
Sahm, Felix
Wick, Wolfgang
Nagel, Armin Michael
Heiland, Sabine
Schlemmer, Heinz-Peter
Bendszus, Martin
Reichenbach, Jürgen Rainer
Radbruch, Alexander
Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
title Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
title_full Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
title_fullStr Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
title_full_unstemmed Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
title_short Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
title_sort quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605431/
https://www.ncbi.nlm.nih.gov/pubmed/23555565
http://dx.doi.org/10.1371/journal.pone.0057924
work_keys_str_mv AT deistungandreas quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT schweserferdinand quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT wiestlerbenedikt quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT abellomario quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT roethkematthias quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT sahmfelix quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT wickwolfgang quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT nagelarminmichael quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT heilandsabine quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT schlemmerheinzpeter quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT bendszusmartin quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT reichenbachjurgenrainer quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma
AT radbruchalexander quantitativesusceptibilitymappingdifferentiatesbetweenblooddepositionsandcalcificationsinpatientswithglioblastoma